Effect of a lifestyle intervention to prevent weight gain at initiation of insulin pump therapy in type 2 diabetes: A randomized, controlled, multicentre trial
- PMID: 37169309
- DOI: 10.1016/j.diabres.2023.110698
Effect of a lifestyle intervention to prevent weight gain at initiation of insulin pump therapy in type 2 diabetes: A randomized, controlled, multicentre trial
Abstract
Insulin pump therapy improves glycaemic control in individuals with type 2 diabetes. However, it may be associated with weight gain.
Aim: To test the effectiveness of a six-month dietary and physical activity intervention, compared to usual care, on weight gain prevention after initiation of insulin pump.
Methods: Multicentre randomized, controlled trial of 54 individuals. Primary endpoint was between group difference in weight gain at six-months.
Results: Weight gain after 6 months of insulin pump treatment did not differ between groups: mean 3.2 (3.9) kg in the control group and 3.9 (3.8) kg in the intervention group, (p = 0.56). HbA1c improved without difference between groups. Post-hoc multivariate analysis of all participants found that weight gain was independently associated with younger age, active smoking, and the magnitude of HbA1c reduction. A 1 % decrease in HbA1c was associated with an increase of 0.94 kg [95 % Confidence Interval 0.47; 1.41], p < 0.001.
Conclusions: Treatment intensification by insulin pump therapy in patients with type 2 diabetes is effective to improve glycaemic control. A gain of about 1 kg per 1 % drop in HbA1c can be expected after insulin treatment intensification. This weight gain was not prevented by a home-base, individualized, 6-months lifestyle intervention program.
Keywords: Actimetry; Body weight; Diet; Insulin pump therapy; Physical activity; Type 2 diabetes.
Copyright © 2023 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: C.B., SL, M.C., H. A., H.B., A.C., C.L., S.G., J.C.B. have nothing to disclose regarding the present paper. L.B. has a clinical trial assistant contract with AGIR à dom. S.G. A.L.B. has received research grants from “Agir Pour les Maladies Chroniques (APMC)”, a foundation from Agir à Dom.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
